What is Vericel?
Headquartered in Cambridge, Massachusetts, Vericel Corporation operates at the intersection of advanced cell biology and medical technology. Since its inception in 1989, the company has evolved from its roots as Aastrom Biosciences into a commercial-stage entity focused on the development and manufacture of differentiated therapies. By providing innovative solutions to orthopedic surgeons and specialized burn care centers, Vericel maintains a critical market position in regenerative medicine. The company's business model relies on high-barrier-to-entry biologic products that address significant unmet medical needs, effectively insulating its revenue streams from broader market volatility while maintaining a strong competitive moat in the specialty healthcare landscape.
How much funding has Vericel raised?
Vericel has raised a total of $313.8M across 14 funding rounds:
Stock Offering
$12.4M
Stock Offering
$20.5M
Share Placement
$38M
Stock Offering
$9M
Private Equity
$15M
Stock Offering
$40.3M
Stock Offering
$20M
Debt
$25M
Stock Offering
$74.8M
Stock Issuance/Offering (2010): $12.4M with participation from Undisclosed
Stock Issuance/Offering (2010): $20.5M led by Undisclosed
Share Placement (2012): $38M supported by Eastern Capital
Stock Issuance/Offering (2013): $9M featuring Undisclosed
Private Equity (2014): $15M backed by Lincoln Park Capital
Stock Issuance/Offering (2014): $40.3M with participation from Undisclosed
Stock Issuance/Offering (2016): $20M led by Undisclosed
Debt (2017): $25M supported by MidCap Financial and Silicon Valley Bank
Stock Issuance/Offering (2018): $74.8M featuring Undisclosed
Key Investors in Vericel
National Institutes of Health
The National Institutes of Health is the primary agency of the United States government responsible for biomedical and health-related research, providing critical support for scientific innovation.
MidCap Financial
MidCap Financial provides flexible, asset-based financing solutions tailored to the needs of growing companies, focusing on efficient capital deployment.
Silicon Valley Bank
Silicon Valley Bank is a specialized financial institution offering commercial banking, investment services, and asset management to the innovation economy.
What's next for Vericel?
Looking ahead, Vericel is positioned to leverage its recent capital influx to scale its commercial operations and potentially expand its therapeutic pipeline. As the company continues to refine its manufacturing processes for autologous cell therapies, the focus will likely shift toward increasing market penetration in the United States. Strategic priorities include optimizing the distribution network for its core products and exploring new clinical indications that align with its existing expertise in tissue repair. By maintaining a disciplined approach to capital allocation, Vericel aims to solidify its leadership in the biopharmaceutical space, ensuring sustainable value creation for stakeholders while advancing the standard of care for patients with severe injuries.
See full Vericel company page
